Erlotinib-induced trichomegaly in a male patient with pancreatic cancer.
In this report we present a case of erlotinib-induced trichomegaly in a male patient who received erlotinib for his pancreatic cancer. Trichomegaly as a side effect of epidermal growth factor receptor (EGFR) inhibitor therapy is uncommon in male patients. Also, it has not been reported previously in a patient with pancreatic cancer. Previous reported cases all involved female lung cancer patients. We emphasize the importance of recognizing the side effects of EGFR inhibitor therapy and its implications on the prognosis of the cancer treated.
Saif
Muhammad Wasif
MW
Gastrointestinal Cancers Program, Yale Cancer Center, and Yale University School of Medicine, New Haven, Connecticut 06520, USA. wasif.saif@yale.edu
Gnanaraj
Joseph
J
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000069347:Erlotinib Hydrochloride; D005138:Eyebrows / Q000187:drug effects* / Q000254:growth & development; D005140:Eyelashes / Q000187:drug effects* / Q000254:growth & development; D005260:Female; D006801:Humans; D006983:Hypertrichosis / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000556:secondary; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011799:Quinazolines / Q000009:adverse effects*
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors